Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | ESRRG | P62508 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
| ▸ | GFER | P55789 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1131315 | 1.00 | MAPT (1.00) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL1129782 | 1.00 | MAPT (1.00) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL15315413 | 0.88 | MAPT (0.79) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL15315410 | 0.88 | ESRRG (1.00) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL15315409 | 0.87 | MAPT (0.77) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL2536737 | 0.86 | MAPT (0.76) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL8243886 | 0.86 | MAPT (0.76) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL12443591 | 0.86 | ESRRG (0.77) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL15315412 | 0.85 | ESRRG (1.00) | MAPTALDH1A1ESRRGKDM4EMEN1 | |
| SCHEMBL9755109 | 0.85 | ESRRG (1.00) | MAPTALDH1A1ESRRGKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264604-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | claimed |
| CN-119432708-A | In vitro induction method of gastric organoids and application thereof | 广州国家实验室 | 2025-02-14 | — | — | CN | claimed |
| CN-115851745-B | Application of substance for regulating Esrrb activity in preparation of product for intervening retinal cleavage disease | 河南省人民医院 | 2023-10-27 | — | — | CN | claimed |
| EP-3019596-B1 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON- PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | HONG GUAN LTD (CN) | 2023-07-05 | — | — | EP | claimed |
| CN-115851745-A | Application of substance for regulating Esrrb activity in preparation of product for intervening retinoschisis | 河南省人民医院 | 2023-03-28 | — | — | CN | claimed |
| CN-108934168-B | Improved methods for reprogramming non-pluripotent cells to pluripotent stem cells | 北昊干细胞与再生医学研究院有限公司 | 2022-05-03 | — | — | CN | claimed |
| US-12599665-B2 | Gene fusions for control of genetically modified cells | A2 BIOTHERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2025264604-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | THE PROCTER & GAMBLE COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250230416-A1 | MULTI DONOR STEM CELL COMPOSITIONS AND METHODS OF MAKING SAME | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250223335-A1 | PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2025-07-10 | — | — | US | disclosed |
| US-12281334-B2 | Multi donor stem cell compositions and methods of making same | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-04-22 | — | — | US | disclosed |
| US-20090281191-A1 | USE OF ORGANIC COMPOUNDS | RANGWALA SHAMINA M | 2009-11-12 | — | — | US | disclosed |
| WO-2009136867-A1 | METHOD OF EFFECTING DE-DIFFERENTIATION OF A CELL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-11-12 | — | — | WO | disclosed |
| US-7544838-B2 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544838-B2 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE (US) | 2009-06-09 | — | — | US | disclosed |
| WO-2007131005-A2 | USE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE | 2006-08-24 | — | — | US | disclosed |
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | ESRRA, ESRRB, ESR2 | MAPT 4297/4885ALDH1A1 866/4885ESRRG 4/4885 |
| US-12599665-B2 | Gene fusions for control of genetically modified cells | BID, ESR1, BCLAF1 | MAPT 911/4885ALDH1A1 4643/4885ESRRG 28/4885 |
| US-20090281191-A1 | USE OF ORGANIC COMPOUNDS | GPR119, PPARG, NR1H2 | MAPT 244/4885ALDH1A1 826/4885ESRRG 6/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | MAPT 411/4885ALDH1A1 4219/4885ESRRG 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.